Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy

The predictive value of measurable residual disease (MRD) for survival in acute myeloid leukemia (AML) has been firmly established younger patients treated with intensive chemotherapy. MRD after treatment decitabine older is unknown. This retrospective analysis included ≥60 years age AML who received an allogeneic hematopoietic cell transplantation (alloHCT) or Of the 133 consecutively transplanted patients, 109 had available pretransplantation analyses (by flowcytometry [threshold 0.1%]). Forty (10-day schedule), and 69 chemotherapy (7 + 3 regimen). Patients were (median 67 versus 64 years) more often (70% 38%). OS alloHCT was comparable both groups. In group, MRD-positive a significantly higher relapse probability (subdistribution hazard ratio [sHR] 4.81; P= .0031) risk death (HR 2.8; .02) compared to MRD-negative patients. group there no significant association between presence (sHR 0.85; .83) 0.72; .60). Pretransplantation receiving does not have similar alloHCT,